SOUTH SAN FRANCISCO, Calif. and SAN CARLOS, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) and Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) today jointly announced an ...
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format ...
The layoffs aren’t letting up at Sutro Biopharma. After halving the antibody-drug conjugate (ADC) biotech’s head count in the spring, the company is waving goodbye to a third of its remaining ...
Sutro helps non-technical users build apps, including their websites, mobile versions, and backends. The startup does this by combining elements of low-code, AI-generated code, and custom code. Here's ...
AI is already transforming the way we search, gather information, create, code, decipher data and more, and now it may democratize the process of building an app, too. A new AI-powered startup called ...
Speaking comes easy to Kevin Montgomery. The 27-year-old Mission District writer is full of clear thoughts and funny anecdotes. But when Montgomery talks about his passion for the Sutro Tower, he gets ...
- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback